Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 897-907

  Farrell, Colm ^a   Hayes, Siobhan ^a   Relan, Anurag ^b   Van Amersfoort, Edwin S ^b   Pijpstra, Rienk ^b   Hack, C Erik ^c  

^a ICON PLC   (United Kingdom)

^b Janssen Biologics   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

hereditary angioedema; NONMEM; pharmacokinetics; recombinant human C1 inhibitor

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; FEMALE; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIMULATION;

HEREDITARY ANGIOEDEMA; NONMEM; PHARMACOKINETICS; RECOMBINANT HUMAN C1 INHIBITOR;

CLINICAL TRIALS AS TOPIC; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPUTER SIMULATION; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS;

EID: 84886728753     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12132     Document Type: Article

References (24)

1. Zuraw BL,. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
2. Cicardi M, Agostini A,. Hereditary angioedema. N Engl J Med 1996; 334: 1666-1667.
3. Landerman NS, Webster ME, Becker EL, Ratcliffe HE,. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962; 33: 330-341.
4. Hack CE, Relan A, van Amersfoort ES, Cicardi M,. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012; 67: 123-130.
5. Beal S, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM User's Guides. (1989-2011). 7.2.0 ed. Ellicott City, MD: Icon Development Solutions, 2011.
6. Ahn JE, Karlsson MO, Dunne A, Ludden TM,. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 401-421.
7. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE,. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827.
8. van Doorn MBA, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE, Schoemaker RC, Cohen AF, Nuijens J,. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876-883.
9. Cicardi M, Zingale L,. Clinical manifestations of hereditary angioedema. J Allergy Clin Immunol 2004; 114: S55-58.
10. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y,. Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the international council for standardization in haematology. Br J Haematol 1995; 89: 748-756.
11. Martinez-Sauger I, Rusicke E, Aygören-Pürsün E, von Hentig N, Klingebiel T, Kruez W,. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 2010; 50: 354-360.
12. Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panov Ska V, Kiessling PC, Schindel F, Craig TJ,. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat hereditary angioedema attacks. Ann Allergy Asthma Immunol 2010; 105: 149-154.
13. Koles K, Van Berkel PH, Pieper FR, Nuijens JH, Mannesse ML, Vliegenthart JF,. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14: 51-64.
14. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein HA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan W-T,. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
15. FDA Advisory Committee Briefing Document Ecallantide, 2009. Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/pulmonary-allergydrugsadvisorycommittee/ucm170334.pdf (last accessed 11 July 2013).
16. Bos IG, Hack CE, Abrahams JP,. Structural and functional aspects of C1-inhibitor. Immunobiology 2002; 205: 518-533.
17. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE,. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem 1996; 271: 12913-12918.
18. Cugno M, Bos I, Lubbers Y, Hack CE, Agostoni A,. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul Fibrinolysis 2001; 12: 253-256.
19. Eldering E, Huijbregts CC, Lubbers YT, Longstaff C, Hack CE,. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem 1992; 267: 7013-7020.
20. Sulikowski T, Patston PA,. The inhibition of TNK-t-PA by C1-inhibitor. Blood Coagul Fibrinolysis 2001; 12: 75-77.
21. Morgan DJ, Bray KM,. Lean body mass as a predictor of drug dosage-implications for drug therapy. Clin Pharmacokinet 1994; 26: 292-307.
22. Späth PJ, Wüthrich B, Bütler R,. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema-evidence of a functionally critical level of C1-inhibitor concentration. Complement 1984; 1: 147-159.
23. European Medicines Agency. CHMP Assessment Report: Ruconest. 24 June 2010. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Public-assessment-report/human/001223/WC500098546.pdf (last assessed 11 July 2013).
24. Baboeram A, Relan CE, Hack M, Mannesse G, Haase B, Oortwijn S, Visscher R,. Pijpstra. 29th European Academy of Allergy and Clinical Immunology Congress. 5-9 June 2010, London. Immunogenicity assessment of recombinant human C1 Inhibitor (rhC1INH).